Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

Vaxcyte (Nasdaq: PCVX) announced the commencement of a proposed underwritten public offering of $500,000,000 of common stock and pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $75,000,000.

The offering is subject to market and other conditions; a shelf registration was automatically effective May 24, 2024, and a preliminary prospectus supplement will be filed with the SEC.

Positive

• Potential capital raise of $500,000,000
• Underwriter option to increase size by $75,000,000
• Shelf registration effective May 24, 2024

Negative

• Creates potential shareholder dilution from offered shares and pre-funded warrants
• Completion is uncertain and dependent on market and other conditions
• Pre-funded warrants increase future share issuance risk if exercised

News Market Reaction

+2.82%

5 alerts

+2.82% News Effect

+16.1% Peak Tracked

-3.0% Trough Tracked

+$190M Valuation Impact

$6.91B Market Cap

0.5x Rel. Volume

On the day this news was published, PCVX gained 2.82%, reflecting a moderate positive market reaction. Argus tracked a peak move of +16.1% during that session. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $190M to the company's valuation, bringing the market cap to $6.91B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Proposed offering size: $500,000,000 Underwriters’ option: $75,000,000 Underwriters’ option period: 30 days +1 more

4 metrics

Proposed offering size $500,000,000 Underwritten public offering of common stock and pre-funded warrants

Underwriters’ option $75,000,000 Additional common stock via 30-day option

Underwriters’ option period 30 days Option to purchase additional common shares

Shelf effectiveness date May 24, 2024 Shelf registration automatically effective upon SEC filing

Market Reality Check

Price: $54.10 Vol: Volume 861,363 vs 20-day ...

normal vol

$54.10 Last Close

Volume Volume 861,363 vs 20-day average 1,093,822 (relative volume 0.79x). normal

Technical Price $51.37 is trading above 200-day MA at $38.19, despite the offering headline.

Peers on Argus

PCVX fell 5.48% while peers like ACAD, ARWR, KRYS and others were down a milder ...

PCVX fell 5.48% while peers like ACAD, ARWR, KRYS and others were down a milder 0.3–2.8%. Scanner data does not flag a coordinated sector move, suggesting a PCVX-specific reaction to the capital raise.

Previous Offering Reports

5 past events · Latest: Sep 06 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Sep 06	Offering closing	Negative	+3.3%	Closed large public offering with full underwriters’ option exercise.
Sep 04	Offering pricing	Negative	+2.7%	Priced $1.3B public offering of common stock and pre-funded warrants.
Sep 03	Offering commencement	Negative	-0.9%	Announced start of $1.0B underwritten public offering and 30-day option.
Feb 02	Offering closing	Negative	-1.5%	Closed $862.5M public offering including full underwriters’ option.
Jan 30	Offering pricing	Negative	+6.0%	Announced pricing of $750M public offering of common stock.

Pattern Detected

Past equity offerings often saw mixed reactions, with several instances of positive price moves despite typically dilutive headlines.

Recent Company History

Over the past two years, PCVX has repeatedly tapped equity markets via underwritten offerings and related transactions. Prior offering announcements in Jan 2024, Feb 2024 and early Sep 2024 covered pricing, commencement and closings, including a notable $1.5 billion raise with full underwriter option exercise. Price reactions ranged from modest declines to gains above 6%, indicating investors sometimes viewed these financings constructively. Today’s proposed offering continues this pattern of sizable equity raises to support the company’s vaccine programs.

Historical Comparison

+2.9% avg move · In the past, PCVX’s offering-related headlines produced an average move of about 2.89%, often skewin...

offering

+2.9%

Average Historical Move offering

In the past, PCVX’s offering-related headlines produced an average move of about 2.89%, often skewing positive. Today’s -5.48% reaction to another proposed offering is more negative than those prior same-tag events.

PCVX has repeatedly executed sizable equity offerings since early 2024, including commencements, pricings and closings, cumulatively raising over a billion dollars to fund development. The new proposed raise continues this established financing pattern.

Market Pulse Summary

This announcement detailed a proposed $500,000,000 underwritten public offering of common stock and ...

Analysis

This announcement detailed a proposed $500,000,000 underwritten public offering of common stock and pre-funded warrants, plus a $75,000,000 30-day underwriters’ option. It follows a pattern of sizable equity financings used to fund vaccine development and related initiatives. Investors may track how the final deal size and pricing compare with prior offerings, as well as updates from recent regulatory filings that outline cash balances, operating losses, and long-term manufacturing commitments, to gauge the balance between funding needs and dilution risk.

Key Terms

underwritten public offering, pre-funded warrants, book-running managers, shelf registration statement, +2 more

6 terms

underwritten public offering financial

"it has commenced an underwritten public offering of $500,000,000"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"offering of $500,000,000 of its common stock and pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

book-running managers financial

"are acting as joint book-running managers for the offering"

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

shelf registration statement regulatory

"A shelf registration statement relating to the offered securities was filed"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to the offering"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Securities and Exchange Commission (SEC) regulatory

"was filed with the Securities and Exchange Commission (SEC)"

A U.S. federal agency that oversees the stock and securities markets, requiring public companies and brokers to register and share accurate financial information so investors can see the facts. It enforces rules, investigates fraud and can pause or change market activity; think of it as a referee whose decisions and investigations affect investor confidence, legal risk and the value of traded securities.

AI-generated analysis. Not financial advice.

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BofA Securities, Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.

A shelf registration statement relating to the offered securities was filed with the Securities and Exchange Commission (SEC) and was automatically effective upon filing on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from BofA Securities NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention: Equity Syndicate Department, 520 Madison Avenue, New York, New York 10022, by telephone at 1-877-821-7388, or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by email at syndicate@leerink.com or by phone at (800) 808-7525, ext. 6105; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 1-888-474-0200 or by email at ecm.prospectus@evercore.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF^®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. 

Contacts:

Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com

Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com

FAQ

What did Vaxcyte (PCVX) announce on January 29, 2026?

Vaxcyte announced a proposed underwritten public offering of $500,000,000 of common stock and pre-funded warrants. According to the company, it may grant underwriters a 30-day option for an additional $75,000,000 and the offering is subject to market conditions.

How much capital is Vaxcyte (PCVX) seeking to raise in the offering?

Vaxcyte is seeking to raise $500,000,000 through the offering of common stock and pre-funded warrants. According to the company, underwriters may purchase up to an additional $75,000,000 within a 30-day option period.

What is a pre-funded warrant in Vaxcyte's (PCVX) offering?

A pre-funded warrant allows investors to buy shares later at minimal additional cost after funding is provided upfront. According to the company, pre-funded warrants are included to accommodate purchasers who face ownership restrictions.

When is the Vaxcyte (PCVX) shelf registration effective and where is the prospectus filed?

The shelf registration was automatically effective on May 24, 2024, and related materials will be filed with the SEC. According to the company, a preliminary prospectus supplement will be available on the SEC website.

How could the offering affect existing Vaxcyte (PCVX) shareholders?

The offering could dilute existing shareholders if new shares and exercised warrants increase share count. According to the company, exact dilution depends on offering size, whether the underwriter option is exercised, and future warrant exercises.